Gastrointestinal Cancers

Gastric and Esophageal Cancers: Clinical Updates and Nursing Implications

Archived NCCN Tumor Boards: Hereditary Gastrointestinal Cancers - Expansion of NCCN Recommendations

The prevalence of genetic predisposition to cancer is greater than initially appreciated.

NCCN Tumor Boards: Hereditary Gastrointestinal Cancers - Expansion of NCCN Recommendations

The prevalence of genetic predisposition to cancer is greater than initially appreciated.

Recorded Presentation from Optimizing Patient Outcomes - Understanding the Mismatch Repair Deficient (dMMR)/Microsatellite-High (MSI-H) Treatment Options in Upper Gastrointestinal Cancers

The standards of care for the treatment of MSI-H/dMMR esophageal, esophagogastric junction, and gastric cancers are constantly evolving.

Updates in the Multidisciplinary Approach for Resectable Gastroesophageal Adenocarcinoma and Peritoneal-Limited Disease
The treatment landscape for gastroesophageal tumors is expanding, including the role of systemic therapy plus surgery. It is essential for healthcare professionals (HCPs) in community and academic settings to be aware of and understand current and emerging treatment options and associated evidence, even that which is limited and may be controversial.
Optimizing Patient Outcomes - Understanding the Mismatch Repair Deficient (dMMR)/Microsatellite-High (MSI-H) Treatment Options in Upper Gastrointestinal Cancers

The standards of care for the treatment of MSI-H/dMMR esophageal, esophagogastric junction, and gastric cancers are constantly evolving.

Archived NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer
ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.
NCCN Tumor Boards: Immune Checkpoint Inhibitors for First-Line Therapy in Esophagogastric/Esophagogastric Junction Cancer
ICIs have become an advantageous treatment option for advanced or metastatic esophagogastric/EGJ cancer. Clinicians need to be aware of and understand the clinical trial data and real-world evidence supporting the use of ICIs, especially for treating MSI-H/dMMR tumors.
Management of MSI-H/dMMR Upper and Lower Gastrointestinal Cancers
Clinicians need to be informed about the importance of MSI-H/dMMR testing in patients with GI tumors and updated on the most recent clinical evidence to ensure that they select the most appropriate treatment options for their patients.

Pages

Subscribe to RSS - Gastric/Esophageal Cancer